Given our previously described findings, we hypothesized that ACTBL2 might enhance cellular viability, proliferation and migration in ovarian cancer, thus serving as a potential explanation for the poor prognosis associated with positive ACTBL2 expression in EOC patients. This evidence concerns the gene ACTBL2 and ovarian carcinoma.